Azitra Inc. (NYSE American: AZTR) announced it has regained compliance with NYSE American's continued listing standards following a regulatory notification dated August 19, 2025.
The Branford, Connecticut-based clinical-stage biopharmaceutical company received written confirmation from NYSE Regulation that it resolved previously disclosed deficiencies under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. As a result, the exchange will discontinue dissemination of the "below compliance" indicator and remove Azitra from its list of noncompliant issuers.
The company remains subject to NYSE Regulation's ongoing monitoring procedures. Under Section 1009(h) of the NYSE American Company Guide, if Azitra fails to meet any continued listing standards within 12 months of the August 19 notification, the exchange may review the circumstances and reassess the company's financial recovery approach. Potential actions include shortening compliance timelines or initiating immediate delisting proceedings.
Azitra develops therapies for precision dermatology and cosmetic proteins, including ATR-COSF, a recombinant protein technology for skincare applications, and ATR-04, an investigational live biotherapeutic targeting EGFR inhibitor-associated rash. The FDA has granted Fast Track designation to ATR-04 for this indication.
Francisco Salva, Chief Executive Officer of Azitra, said the company is pleased to have resolved the matter and regained full compliance with NYSE American's continued listing standards.
